Division of Oncology

Medicine & Life Sciences

1. Neoplasms 100%
2. Breast Neoplasms 58%
3. Therapeutics 56%
4. Survival 54%
5. Mutation 51%
6. Drug Therapy 44%
7. Multiple Myeloma 44%
8. Acute Myeloid Leukemia 43%
9. Non-Small Cell Lung Carcinoma 39%
10. T-Lymphocytes 36%
11. Genes 35%
12. Progression-Free Survival 34%
13. Genome 29%
14. Bone Marrow 29%
15. Hematopoietic Stem Cells 29%
16. Leukemia 26%
17. Rituximab 26%
18. Cell Transplantation 26%
19. Non-Hodgkin's Lymphoma 25%
20. Transplants 24%
21. Proteins 24%
22. Immunotherapy 23%
23. Recurrence 21%
24. Graft vs Host Disease 21%
25. Stem Cells 21%
26. Hodgkin Disease 20%
27. Granulocyte Colony-Stimulating Factor 20%
28. Lymphoma 20%
29. Natural Killer Cells 19%
30. Prostatic Neoplasms 19%
31. Renal Cell Carcinoma 19%
32. Clinical Trials 19%
33. Safety 19%
34. Mantle-Cell Lymphoma 18%
35. Neoplasm Metastasis 17%
36. HIV-1 17%
37. Lymphoma, Large B-Cell, Diffuse 17%
38. High-Throughput Nucleotide Sequencing 17%
39. Pancreatic Neoplasms 17%
40. Adenocarcinoma 17%
41. Confidence Intervals 16%
42. Sarcoma 16%
43. Allogeneic Cells 16%
44. Myelodysplastic Syndromes 16%
45. Radiotherapy 16%
46. Lung Neoplasms 16%
47. DNA 15%
48. Cyclophosphamide 15%
49. Follicular Lymphoma 15%
50. Growth 15%
51. Biomarkers 15%
52. Triple Negative Breast Neoplasms 15%
53. Lenalidomide 14%
54. Cell Line 14%
55. Chimeric Antigen Receptors 14%
56. Macrophages 14%
57. Hematopoiesis 14%
58. Guidelines 13%
59. Stem Cell Transplantation 13%
60. Brentuximab Vedotin 13%
61. Melanoma 13%
62. Glioblastoma 13%
63. Deltaretrovirus 13%
64. Bortezomib 13%
65. Mucopolysaccharidosis VII 13%
66. B-Cell Lymphoma 13%
67. Doxorubicin 13%
68. gemcitabine 13%
69. HIV 13%
70. Gene Expression 12%
71. Clone Cells 12%
72. Population 12%
73. Apoptosis 12%
74. Hematologic Neoplasms 12%
75. Paclitaxel 11%
76. Docetaxel 11%
77. plerixafor octahydrochloride 11%
78. Carboplatin 11%
79. Hematopoietic Stem Cell Transplantation 11%
80. Lymphocytes 11%
81. Heterografts 11%
82. Maintenance 11%
83. pembrolizumab 11%
84. Cytokines 11%
85. Phosphotransferases 10%
86. Proteomics 10%
87. Ligands 10%
88. B-Lymphocytes 10%
89. Hematopoietic Stem Cell Mobilization 10%
90. Bendamustine Hydrochloride 10%
91. Phenotype 10%
92. Tissue Donors 10%
93. Human T-lymphotropic virus 1 10%
94. Carcinoma 10%
95. Transplantation 10%
96. Neutrophils 10%
97. Cisplatin 10%
98. Precursor Cell Lymphoblastic Leukemia-Lymphoma 10%
99. Protein-Tyrosine Kinases 10%
100. Epigenomics 10%